|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).
|
25305506 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recently, increasing evidences indicate that BRAF((V600E)) mutation is a specific molecular feature and driver of the serrated pathway, and proximal serrated polyps with BRAF((V600E)) mutation have a high risk of progression to malignancy.
|
25550768 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy.
|
27818286 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of FNMTC.
|
29895015 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for thyroid cancer if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in Braf(V600E) mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas.
|
25848750 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation.
|
19883729 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer.
|
24717435 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two patients with treatment-refractory high-grade colorectal neuroendocrine tumors harboring BRAF(V600E) exhibited rapid and durable response to combined BRAF-MEK inhibition, providing the first clinical evidence of efficacy in this aggressive tumor type.Cancer Discov; 6(6); 594-600.
|
27048246 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using patient-derived (V600E)BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo.
|
27617932 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
|
29422527 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, in cases of indeterminate FNA with unclassifiable atypical cells BRAF (V600E) mutated, the possibility of a localization of hystiocytosis or a secondary thyroid malignancy should be taken into account.
|
26782803 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The recognition of this functional trilogy provides insight on how BRAF(V600E) determines cancer initiation, progression, and invasiveness in PTC, also identifying new therapeutic targets for the treatment of highly aggressive forms.
|
21903858 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding of tumor-specific patterns of NR expression, as well as significant differences in NR expression between BRAF(V600E) and wild type BRAF PTC, provides a basis for further mechanistic studies and highlights potential novel therapeutic targets for this malignancy.
|
24559275 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |